Duncker Streett & Co. Inc. grew its holdings in shares of Celgene Co. (NASDAQ:CELG) by 15.6% in the fourth quarter, Holdings Channel reports. The institutional investor owned 12,185 shares of the biopharmaceutical company’s stock after purchasing an additional 1,640 shares during the period. Duncker Streett & Co. Inc.’s holdings in Celgene were worth $1,272,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also made changes to their positions in the company. BlackRock Inc. increased its position in shares of Celgene by 5.7% during the second quarter. BlackRock Inc. now owns 56,725,342 shares of the biopharmaceutical company’s stock worth $7,366,919,000 after purchasing an additional 3,084,227 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Celgene by 3.1% during the second quarter. Vanguard Group Inc. now owns 53,527,210 shares of the biopharmaceutical company’s stock worth $6,951,579,000 after purchasing an additional 1,610,056 shares in the last quarter. Jennison Associates LLC increased its position in shares of Celgene by 11.5% during the third quarter. Jennison Associates LLC now owns 14,962,407 shares of the biopharmaceutical company’s stock worth $2,181,818,000 after purchasing an additional 1,546,673 shares in the last quarter. FMR LLC increased its position in shares of Celgene by 5.9% during the second quarter. FMR LLC now owns 12,594,467 shares of the biopharmaceutical company’s stock worth $1,635,643,000 after purchasing an additional 697,250 shares in the last quarter. Finally, Franklin Resources Inc. increased its position in shares of Celgene by 3.3% during the second quarter. Franklin Resources Inc. now owns 11,080,093 shares of the biopharmaceutical company’s stock worth $1,439,025,000 after purchasing an additional 349,974 shares in the last quarter. 77.84% of the stock is owned by institutional investors.
Celgene Co. (CELG) opened at $93.89 on Thursday. The company has a debt-to-equity ratio of 2.29, a quick ratio of 4.80 and a current ratio of 4.99. Celgene Co. has a 52-week low of $88.32 and a 52-week high of $147.17. The stock has a market capitalization of $70,591.68, a P/E ratio of 26.23, a price-to-earnings-growth ratio of 0.66 and a beta of 1.49.
Celgene declared that its board has initiated a stock buyback program on Wednesday, February 14th that allows the company to buyback $5.00 billion in outstanding shares. This buyback authorization allows the biopharmaceutical company to reacquire shares of its stock through open market purchases. Stock buyback programs are generally a sign that the company’s management believes its stock is undervalued.
In other Celgene news, insider Mark J. Alles bought 3,260 shares of the company’s stock in a transaction on Thursday, February 8th. The shares were bought at an average price of $91.90 per share, for a total transaction of $299,594.00. Following the transaction, the insider now owns 178,904 shares of the company’s stock, valued at approximately $16,441,277.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Gilla Kaplan sold 9,250 shares of the business’s stock in a transaction that occurred on Thursday, February 15th. The stock was sold at an average price of $95.99, for a total value of $887,907.50. Following the transaction, the director now owns 94,801 shares in the company, valued at approximately $9,099,947.99. The disclosure for this sale can be found here. Insiders own 0.95% of the company’s stock.
A number of analysts have recently commented on CELG shares. BMO Capital Markets lifted their target price on Celgene from $148.00 to $155.00 and gave the stock an “outperform” rating in a research report on Friday, November 17th. Cantor Fitzgerald set a $112.00 target price on Celgene and gave the stock a “hold” rating in a research report on Wednesday, January 17th. Morgan Stanley upgraded Celgene from an “underweight” rating to an “equal weight” rating in a research report on Friday, October 27th. Cann reiterated a “buy” rating on shares of Celgene in a research report on Thursday, October 26th. Finally, Citigroup cut their target price on Celgene from $140.00 to $102.00 and set a “neutral” rating on the stock in a research report on Friday, October 27th. Two equities research analysts have rated the stock with a sell rating, twelve have assigned a hold rating, eighteen have issued a buy rating and two have issued a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $130.25.
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.